Aptar's UDS Powder system enters ENA Respiratory's POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.
Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.
Centivax has begun Phase 1 testing of its universal flu vaccine Centi-Flu 01. Find out what this trial could change for influenza prevention.
Hyundai Bioscience enters U.S. Phase 2 trials for Xafty, a broad-spectrum antiviral targeting flu, RSV, and COVID. Find out what this means for future pandemics.